Company / EPS (Diluted)
Merck & Co. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.14
FY2025
5-year range
$0.14 / $5.71
FY2021-FY2025
Trend
-97.5%
vs FY2024
Sector context
#44 of 204
Health Care
What the data says
Merck & Co.'s eps (diluted) of $0.14 is higher than 78% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $0.14 in FY2025 to $5.71 in FY2024.
Based on SEC 10-K filings.
0.14 in FY2025 with a 5-year CAGR of -43.0%. Top quartile in the Health Care sector.
Declined from $5.14 to $0.14 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -63.1%
- 5-Year CAGR
- -43.0%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 204This company $0.14 Sector average -$0.89
▼
+115.8% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 97.5% year-over-year.
- Ranks #44 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.14 | -97.5% |
| FY2024 | $5.71 | +11.1% |
| FY2023 | $5.14 | +84.9% |
| FY2022 | $2.78 | -27.0% |
| FY2021 | $3.81 | +64.2% |
| FY2020 | $2.32 | +166.7% |
| FY2019 | $0.87 | -38.3% |
| FY2018 | $1.41 | -9.6% |
| FY2017 | $1.56 | -61.7% |
| FY2016 | $4.07 | +176.9% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026